echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Amgen Announces New Data from Two OLE Studies of PCSK9 Inhibitor Repatha in ASCVD

    Amgen Announces New Data from Two OLE Studies of PCSK9 Inhibitor Repatha in ASCVD

    • Last Update: 2022-05-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Compilenewborn

    Recently, Amgen announced the top-line results of two open-label extension (OLE) studies of the PCSK9 inhibitor lipid-lowering drug Repatha (Repatha, generic name: evolocumab) Phase 3 FOURIER cardiovascular outcomes trial


    The FOURIER-OLE study consisted of Study 20130295 (NCT02867813), which enrolled 5035 patients in Eastern Europe and the United States, and Study 20160250 (NCT03080935), which enrolled 1600 patients in Western Europe


    Additionally, during the OLE study, medically significant and sustained reductions in low-density lipoprotein cholesterol (LDL-C) levels were observed, with more than 85% of patients achieving LDL-C levels <40 mg/dL


    Other study measures included levels of non-HDL cholesterol, apolipoprotein B, total cholesterol, lipoprotein(a), triglycerides, high density lipoprotein cholesterol, very low density lipoprotein cholesterol, and apolipoprotein A-1.


    Detailed findings will be shared with regulatory agencies and will be presented at a medical congress later this year


    Repatha is a monoclonal antibody that binds to the proprotein convertase subtilisin kexin type 9 (PCSK9), inhibits the binding of circulating PCSK9 to the low-density lipoprotein (LDL) receptor (LDLR), and prevents PCSK9-mediated LDLR is degraded so that LDLR can be recycled back to the surface of hepatocytes


    The results of the two OLE studies published this time confirmed the good safety profile of long-term use of Repahta to lower LDL-C


    Reference source: AMGEN ANNOUNCES RESULTS FROM TWO OPEN LABEL EXTENSION STUDIES OF REPATHA® (EVOLOCUMAB)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.